Healthcare entity
All 1 tracked stories fall under one category: medical-devices. BellaSeno is most often covered alongside Polycaprolactone, which appears in 1 of these 1 story. We currently track 1 Healthcare story that mention BellaSeno, all published on July 2, 2026. Each carries 3 original sources on average.
Last mentioned: Jul 2, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: medical-devices. BellaSeno is most often covered alongside Polycaprolactone, which appears in 1 of these 1 story. We currently track 1 Healthcare story that mention BellaSeno, all published on July 2, 2026. Each carries 3 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering BellaSeno. Shared-story counts are live from our verified record — not editorial picks.
30-patient milestone announced
BellaSeno reports that 30 women have now been treated (19 from the initial study + 11 in the pivotal trial) and highlights progress toward global market entry.
Two-year outcomes presented at The Aesthetic MEET 2026
Professor Anand Deva presents two-year follow-up data showing no scaffold-related complications and 83% mean breast volume retention.
Pivotal clinical trial launched
BellaSeno starts its pivotal trial in Australia to gather evidence for broader regulatory approval and global commercialization.
Initial study enrollment completes
The 19-patient first-in-human safety cohort is fully enrolled; patients are followed for two years.
First-in-human safety study begins
BellaSeno initiates a 19-patient clinical investigation of its breast scaffolds in Australia, aimed at assessing initial safety and tissue regeneration.
BellaSeno announced two-year follow-up data from its first-in-human breast scaffold trial, showing an 83% mean volume retention and zero scaffold-related complications in 19 patients. An additional 11 patients are enrolled in a pivotal Australian trial, with global commercialization as the next goal.
Source: Globe Newswire · Globenewswire_fr
BellaSeno is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
